Acer therapeutics and relief therapeutics announce acer-001 ind submission for the treatment of maple syrup urine disease

Phase 2a trial initiation planned for the first half of 2023 subject to ind clearance and available capital phase 2a trial initiation planned for the first half of 2023 subject to ind clearance and available capital
ACER Ratings Summary
ACER Quant Ranking